{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:01:04Z","timestamp":1790701264217,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Health Research BC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-01007-w","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:11:03Z","timestamp":1790698263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A biomarker-driven approach to targeting polyamine depletion in triple negative breast cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Chloe A. K.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7016-9037","authenticated-orcid":false,"given":"Thomas J.","family":"Velenosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"4","key":"1007_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):1154\u201362. https:\/\/doi.org\/10.1038\/s41591-025-03502-3.","journal-title":"Nat Med"},{"key":"1007_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010. PubMed PMID: 36084384; PubMed Central PMCID: PMC9465273.","journal-title":"Breast"},{"issue":"3","key":"1007_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"Cancer J Clin"},{"issue":"4","key":"1007_CR4","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3390\/jcm12041524","volume":"12","author":"J Lee","year":"2023","unstructured":"Lee J. Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). J Clin Med. 2023;12(4):1524. https:\/\/doi.org\/10.3390\/jcm12041524 PubMed PMID: 36836059; PubMed Central PMCID: PMC9962369.","journal-title":"J Clin Med"},{"issue":"3","key":"1007_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321(3):288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323.","journal-title":"JAMA"},{"issue":"10087","key":"1007_CR6","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/S0140-6736(","volume":"389","author":"C Denkert","year":"2017","unstructured":"Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer\u2014the road to new treatment strategies. Lancet. 2017;389(10087):2430\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(. 16)32454-0 PubMed PMID: 27939063.","journal-title":"Lancet"},{"issue":"7","key":"1007_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/oncolo\/oyae","volume":"29","author":"A LeVee","year":"2024","unstructured":"LeVee A, Wong M, Flores S, Ruel N, McArthur H, Waisman J, et al. Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis. Oncologist. 2024;29(7):566\u201374. https:\/\/doi.org\/10.1093\/oncolo\/oyae. 064 PubMed PMID: 38656345; PubMed Central PMCID: PMC11224989.","journal-title":"Oncologist"},{"key":"1007_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13053-023-00249-1","volume":"21","author":"E Sivina","year":"2023","unstructured":"Sivina E, Blumberga L, Purkalne G, Irmejs A. Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer \u2013 single hospital experience. Hered Cancer Clin Pract. 2023;21:4. https:\/\/doi.org\/10.1186\/s13053-023-00249-1. PubMed PMID: 36922883; PubMed Central PMCID: PMC10018905.","journal-title":"Hered Cancer Clin Pract"},{"issue":"8","key":"1007_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andr\u00e9 F, Tordai A, Mejia JA, et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. JCO. 2008;26(8):1275\u201381. https:\/\/doi.org\/10.1200\/JCO.2007.14.4147.","journal-title":"JCO"},{"issue":"9","key":"1007_CR10","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/iub.230","volume":"61","author":"AE Pegg","year":"2009","unstructured":"Pegg AE. Mammalian Polyamine Metabolism and Function. IUBMB Life. 2009;61(9):880\u201394. https:\/\/doi.org\/10.1002\/iub.230. PubMed PMID: 19603518; PubMed Central PMCID: PMC2753421.","journal-title":"IUBMB Life"},{"issue":"2","key":"1007_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00726-009-0396-7","volume":"38","author":"E Agostinelli","year":"2010","unstructured":"Agostinelli E, Marques MPM, Calheiros R, Gil FPSC, Tempera G, Viceconte N, et al. Polyamines: fundamental characters in chemistry and biology. Amino Acids. 2010;38(2):393\u2013403. https:\/\/doi.org\/10.1007\/s00726-009-0396-7.","journal-title":"Amino Acids"},{"issue":"11","key":"1007_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41568-018-0050-3","volume":"18","author":"RA Casero","year":"2018","unstructured":"Casero RA, Murray Stewart T, Pegg AE. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer. 2018;18(11):681\u201395. https:\/\/doi.org\/10.1038\/s41568-018-0050-3.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1007_CR13","doi-asserted-by":"publisher","first-page":"E995","DOI":"10.1152\/ajpendo.90217.2008","volume":"294","author":"AE Pegg","year":"2008","unstructured":"Pegg AE. Spermidine\/spermine-N1-acetyltransferase: a key metabolic regulator. Am J Physiology-Endocrinology Metabolism. 2008;294(6):E995\u20131010. https:\/\/doi.org\/10.1152\/ajpendo.90217.2008.","journal-title":"Am J Physiology-Endocrinology Metabolism"},{"issue":"1","key":"1007_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41698-022-00313-4","volume":"6","author":"TJ Velenosi","year":"2022","unstructured":"Velenosi TJ, Krausz KW, Hamada K, Dorsey TH, Ambs S, Takahashi S, et al. Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer. NPJ Precis Oncol. 2022;6(1):70. https:\/\/doi.org\/10.1038\/s41698-022-00313-4. PubMed PMID: 36207498; PubMed Central PMCID: PMC9547066.","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"1007_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/BF01209602","volume":"121","author":"M Sugimoto","year":"1995","unstructured":"Sugimoto M, Hiramatsu K, Kamei S, Kinoshita K, Hoshino M, Iwasaki K, et al. Significance of urinaryN 1,N 8-diacetylspermidine andN 1,N 12-diacetylspermine as indicators of neoplastic diseases. J Cancer Res Clin Oncol. 1995;121(5):317\u20139. 01209602 PubMed PMID: 7768972; PubMed Central PMCID: PMC12200966.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"1007_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s004320050102","volume":"123","author":"K Hiramatsu","year":"1997","unstructured":"Hiramatsu K, Sugimoto M, Kamei S, Hoshino M, Kinoshita K, Iwasaki K, et al. Diagnostic and prognostic usefulness of N 1,N 8-diacetylspermidine and N 1,N 12-diacetylspermine in urine as novel markers of malignancy. J Cancer Res Clin Oncol. 1997;123(10):539\u201345. 004320050102 PubMed PMID: 9393587; PubMed Central PMCID: PMC12201237.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1007_CR17","doi-asserted-by":"publisher","first-page":"115717","DOI":"10.1016\/j.ab.2024.115717","volume":"697","author":"D Bhattacharyya","year":"2025","unstructured":"Bhattacharyya D, LeVatte MA, Singh U, Issac F, Karim M, Ali S, et al. A novel colorimetric assay for the detection of urinary N1, N12-diacetylspermine, a known biomarker for colorectal cancer. Anal Biochem. 2025;697:115717. https:\/\/doi.org\/10.1016\/j.ab.2024.115717.","journal-title":"Anal Biochem"},{"issue":"10","key":"1007_CR18","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1002\/ijc.34434","volume":"152","author":"S Jordaens","year":"2023","unstructured":"Jordaens S, Zwaenepoel K, Tjalma W, Deben C, Beyers K, Vankerckhoven V, et al. Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods. Int J Cancer. 2023;152(10):2186\u2013205. https:\/\/doi.org\/10.1002\/ijc.34434.","journal-title":"Int J Cancer"},{"issue":"23","key":"1007_CR19","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.cca.2010.07.018","volume":"411","author":"Y Umemori","year":"2010","unstructured":"Umemori Y, Ohe Y, Kuribayashi K, Tsuji N, Nishidate T, Kameshima H, et al. Evaluating the utility of N1,N12-diacetylspermine and N1,N8-diacetylspermidine in urine as tumor markers for breast and colorectal cancers. Clin Chim Acta. 2010;411(23):1894\u20139. https:\/\/doi.org\/10.1016\/j.cca.2010.07.018.","journal-title":"Clin Chim Acta"},{"issue":"10","key":"1007_CR20","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/bjc.2015.349","volume":"113","author":"Y Takahashi","year":"2015","unstructured":"Takahashi Y, Sakaguchi K, Horio H, Hiramatsu K, Moriya S, Takahashi K, et al. Urinary N1, N12-diacetylspermine is a non-invasive marker for the diagnosis and prognosis of non-small-cell lung cancer. Br J Cancer. 2015;113(10):1493\u2013501. https:\/\/doi.org\/10.1038\/bjc.2015.349. PubMed PMID: 26505680; PubMed Central PMCID: PMC4815893.","journal-title":"Br J Cancer"},{"issue":"8","key":"1007_CR21","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-04-2275","volume":"11","author":"K Hiramatsu","year":"2005","unstructured":"Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, et al. N1,N12-Diacetylspermine as a Sensitive and Specific Novel Marker for Early- and Late-Stage Colorectal and Breast Cancers. Clin Cancer Res. 2005;11(8):2986\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2275.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1007_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/jb\/mvi141","volume":"138","author":"T Miki","year":"2005","unstructured":"Miki T, Hiramatsu K, Kawakita M. Interaction of N1,N12-Diacetylspermine with Polyamine Transport Systems of Polarized Porcine Renal Cell Line LLC-PK1. J Biochem. 2005;138(4):479\u201384. https:\/\/doi.org\/10.1093\/jb\/mvi141.","journal-title":"J Biochem"},{"key":"1007_CR23","doi-asserted-by":"publisher","unstructured":"Mamont PS, Claverie N, Gerhart F. Fluorine-Containing Polyamines: Biochemistry and Potential Applications. In: Zappia V, Pegg AE, editors. Progress in Polyamine Research: Novel Biochemical, Pharmacological, and Clinical Aspects [Internet]. Boston, MA: Springer US; 1988 [cited 2026 Mar 6]. pp. 691\u2013706. Available from: https:\/\/doi.org\/10.1007\/978-1-4684-5637-0_61.","DOI":"10.1007\/978-1-4684-5637-0_61"},{"issue":"2","key":"1007_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00280-004-0786-1","volume":"54","author":"E Gabrielson","year":"2004","unstructured":"Gabrielson E, Tully E, Hacker A, Pegg AE, Davidson NE, Casero RA. Induction of spermidine\/spermine N1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N1,N11-diethylnorspermine. Cancer Chemother Pharmacol. 2004;54(2):122\u20136. https:\/\/doi.org\/10.1007\/s00280-004-0786-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1007_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41467-019-13950-4","volume":"11","author":"HC Affronti","year":"2020","unstructured":"Affronti HC, Rowsam AM, Pellerite AJ, Rosario SR, Long MD, Jacobi JJ, et al. Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy. Nat Commun. 2020;11(1):52. https:\/\/doi.org\/10.1038\/s41467-019-13950-4.","journal-title":"Nat Commun"},{"issue":"25","key":"1007_CR26","doi-asserted-by":"publisher","first-page":"19118","DOI":"10.1016\/S0021-9258","volume":"268","author":"M Fogel-Petrovic","year":"1993","unstructured":"Fogel-Petrovic M, Shappell NW, Bergeron RJ, Porter CW. Polyamine and polyamine analog regulation of spermidine\/spermine N1-acetyltransferase in MALME-3\u00a0M human melanoma cells. J Biol Chem. 1993;268(25):19118\u201325. https:\/\/doi.org\/10.1016\/S0021-9258. (17)46742-1 PubMed PMID: 8360194.","journal-title":"J Biol Chem"},{"issue":"45","key":"1007_CR27","doi-asserted-by":"publisher","first-page":"14436","DOI":"10.1021\/bi9612273","volume":"35","author":"M Fogel-Petrovic","year":"1996","unstructured":"Fogel-Petrovic M, Vujcic S, Brown PJ, Haddox MK, Porter CW. Effects of Polyamines, Polyamine Analogs, and Inhibitors of Protein Synthesis on Spermidine\u2013Spermine N1-Acetyltransferase Gene Expression. Biochemistry. 1996;35(45):14436\u201344. https:\/\/doi.org\/10.1021\/bi9612273.","journal-title":"Biochemistry"},{"issue":"11","key":"1007_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41568-018-0050-3","volume":"18","author":"RA Casero","year":"2018","unstructured":"Casero RA, Murray Stewart T, Pegg AE. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer. 2018;18(11):681\u201395. https:\/\/doi.org\/10.1038\/s41568-018-0050-3.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1007_CR29","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.18632\/oncotarget.13582","volume":"8","author":"C Wang","year":"2016","unstructured":"Wang C, Ruan P, Zhao Y, Li X, Wang J, Wu X, et al. Spermidine\/spermine N1-acetyltransferase regulates cell growth and metastasis via AKT\/\u03b2-catenin signaling pathways in hepatocellular and colorectal carcinoma cells. Oncotarget. 2016;8(1):1092\u2013109. https:\/\/doi.org\/10.18632\/oncotarget.13582. PubMed PMID: 27901475; PubMed Central PMCID: PMC5352037.","journal-title":"Oncotarget"},{"issue":"4","key":"1007_CR30","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3892\/or.2011.1592","volume":"27","author":"Y Tian","year":"2012","unstructured":"Tian Y, Wang S, Wang B, Zhang J, Jiang R, Zhang W. Overexpression of SSAT by DENSPM treatment induces cell detachment and apoptosis in glioblastoma. Oncol Rep. 2012;27(4):1227\u201332. https:\/\/doi.org\/10.3892\/or.2011.1592. PubMed PMID: 22179681; PubMed Central PMCID: PMC3583519.","journal-title":"Oncol Rep"},{"issue":"6","key":"1007_CR31","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00280-013-2293-8","volume":"72","author":"L Goyal","year":"2013","unstructured":"Goyal L, Supko JG, Berlin J, Blaszkowsky LS, Carpenter A, Heuman DM, et al. Phase 1 study of N(1),N(11)\u2013diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2013;72(6):1305\u201314. https:\/\/doi.org\/10.1007\/s00280-013-2293-8. PubMed PMID: 24121453.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1007_CR32","first-page":"684","volume":"8","author":"HA Hahm","year":"2002","unstructured":"Hahm HA, Ettinger DS, Bowling K, Hoker B, Chen TL, Zabelina Y, et al. Phase I Study of N1,N11-Diethylnorspermine in Patients with Non-Small Cell Lung Cancer1. Clin Cancer Res. 2002;8(3):684\u201390.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1007_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1023\/A:1006448516938","volume":"19","author":"RR Streiff","year":"2001","unstructured":"Streiff RR, Bender JF. Phase I Study of N1-N11-Diethylnorspermine (DENSPM) Administered TID for 6 Days in Patients with Advanced Malignancies. Invest New Drugs. 2001;19(1):29\u201339. https:\/\/doi.org\/10.1023\/A:1006448516938.","journal-title":"Invest New Drugs"},{"issue":"16","key":"1007_CR34","first-page":"5922","volume":"9","author":"AC Wolff","year":"2003","unstructured":"Wolff AC, Armstrong DK, Fetting JH, Carducci MK, Riley CD, Bender JF, et al. A Phase II Study of the Polyamine Analog N1,N11-Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer. Clin Cancer Res. 2003;9(16):5922\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1007_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00280-020-04201-1","volume":"87","author":"T Murray Stewart","year":"2021","unstructured":"Murray Stewart T, Von Hoff D, Fitzgerald M, Marton LJ, Becerra CHR, Boyd TE, et al. A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Cancer Chemother Pharmacol. 2021;87(1):135\u201344. https:\/\/doi.org\/10.1007\/s00280-020-04201-1. PubMed PMID: 33215270; PubMed Central PMCID: PMC7855804.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1007_CR36","doi-asserted-by":"publisher","unstructured":"Zabala-Letona A, Pujana-Vaquerizo M, Martinez-Laosa B, Ponce-Rodriguez M, Garcia-Longarte S, Mendizabal I, et al. Polyamine-dependent metabolic shielding regulates alternative splicing. Nature. 2026;1\u201310. https:\/\/doi.org\/10.1038\/s41586-025-09965-1.","DOI":"10.1038\/s41586-025-09965-1"},{"issue":"36","key":"1007_CR37","doi-asserted-by":"publisher","first-page":"2309903","DOI":"10.1002\/advs.202309903","volume":"11","author":"W Tian","year":"2024","unstructured":"Tian W, Zhu L, Luo Y, Tang Y, Tan Q, Zou Y, et al. Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple-Negative Breast Cancer. Adv Sci (Weinh). 2024;11(36):2309903. https:\/\/doi.org\/10.1002\/advs.202309903. PubMed PMID: 39073262; PubMed Central PMCID: PMC11423137.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"1007_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the Cancer Dependency Map. Nat Rev Cancer. 2025;25(1):59\u201373. https:\/\/doi.org\/10.1038\/s41568-024-00763-x.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1007_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63\u201375. https:\/\/doi.org\/10.1007\/s10557-016-6711-0. PubMed PMID: 28185035; PubMed Central PMCID: PMC5346598.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"1007_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00280-022-04400-y","volume":"89","author":"RE Nicoletto","year":"2022","unstructured":"Nicoletto RE, Ofner CM. Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemother Pharmacol. 2022;89(3):285\u2013311. https:\/\/doi.org\/10.1007\/s00280-022-04400-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1007_CR41","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1261\/rna.39806","volume":"12","author":"MT Hyv\u00f6nen","year":"2006","unstructured":"Hyv\u00f6nen MT, Uimari A, Kein\u00e4nen TA, Heikkinen S, Pellinen R, Wahlfors T, et al. Polyamine-regulated unproductive splicing and translation of spermidine\/spermine N1-acetyltransferase. RNA. 2006;12(8):1569\u201382. https:\/\/doi.org\/10.1261\/rna.39806. PubMed PMID: 16809818; PubMed Central PMCID: PMC1524884.","journal-title":"RNA"},{"issue":"7","key":"1007_CR42","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Al Bakir M, Hamilton EG, Diehn M, Andr\u00e9 F, Roy-Chowdhuri S, et al. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617\u201335. https:\/\/doi.org\/10.1016\/j.cell.2024.02.041.","journal-title":"Cell"},{"issue":"5","key":"1007_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2012;2(5):401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095.","journal-title":"Cancer Discov"},{"issue":"6","key":"1007_CR44","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/jnci\/djz","volume":"112","author":"JF Fahrmann","year":"2019","unstructured":"Fahrmann JF, Vykoukal J, Fleury A, Tripathi S, Dennison JB, Murage E, et al. Association Between Plasma Diacetylspermine and Tumor Spermine Synthase With Outcome in Triple-Negative Breast Cancer. J Natl Cancer Inst. 2019;112(6):607\u201316. https:\/\/doi.org\/10.1093\/jnci\/djz. 182 PubMed PMID: 31503278; PubMed Central PMCID: PMC7301069.","journal-title":"J Natl Cancer Inst"},{"key":"1007_CR45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","volume":"14","author":"E Fountzilas","year":"2022","unstructured":"Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med. 2022;14:101. https:\/\/doi.org\/10.1186\/s13073-022-01102-1. PubMed PMID: 36045401; PubMed Central PMCID: PMC9428375.","journal-title":"Genome Med"},{"issue":"1","key":"1007_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","volume":"9","author":"XP Duan","year":"2024","unstructured":"Duan XP, Qin BD, Jiao XD, Liu K, Wang Z, Zang YS. New clinical trial design in precision medicine: discovery, development and direction. Sig Transduct Target Ther. 2024;9(1):57. https:\/\/doi.org\/10.1038\/s41392-024-01760-0.","journal-title":"Sig Transduct Target Ther"},{"issue":"5","key":"1007_CR47","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/0008-5472.CAN-25-1532","volume":"86","author":"R Kumar","year":"2026","unstructured":"Kumar R, Jonnatan S, Sanin DE, Vakkala V, Kadam A, Kumar S, et al. Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer. Cancer Res. 2026;86(5):1148\u201365. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-1532. PubMed PMID: 41270152; PubMed Central PMCID: PMC12758111.","journal-title":"Cancer Res"},{"issue":"10","key":"1007_CR48","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0090-9556(25)06756-X","volume":"23","author":"RJ Bergeron","year":"1995","unstructured":"Bergeron RJ, Weimar WR, Luchetta G, Streiff RR, Wiegand J, Perrin J, et al. Metabolism and pharmacokinetics of N1,N11-diethylnorspermine. Drug Metab Dispos. 1995;23(10):1117\u201325. PubMed PMID: 8654201.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1007_CR49","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00280-020-04082-4","volume":"85","author":"TM Stewart","year":"2020","unstructured":"Stewart TM, Desai AA, Fitzgerald ML, Marton LJ, Casero RA. A Phase I dose-escalation study of the polyamine analogue PG-11047 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020;85(6):1089\u201396. https:\/\/doi.org\/10.1007\/s00280-020-04082-4. PubMed PMID: 32447421; PubMed Central PMCID: PMC7337042.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-01007-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:11:05Z","timestamp":1790698265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-01007-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-01007-w","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were approved by the University of British Columbia Animal Care Committee and conducted in accordance with the guidelines of the Canadian Council on Animal Care. The maximum tumor burden permitted by the approved animal protocol was 2000 mm\n                      3\n                      and was not exceeded in this study. All PDX models were commercially acquired from Jackson Labs and thus, a clinical research ethics protocol was not applicable for this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"126"}}